Neovacs and Stellar Biotechnologies Announce Launch of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Neovacs and Stellar Biotechnologies Announce Launch of Neostell, Joint Venture to Manufacture Kinoids

PARIS, BOSTON, and PORT HUENEME, Calif., July 19, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV) and STELLAR BIOTECHNOLOGIES Inc. (Nasdaq: SBOT ) today announced the start of their joint venture company, Neostell SAS, with the holding of its first general assembly.  At the meeting, the bylaws for Neostell were approved and the Administrative Board and management team were appointed.

The following executives were appointed to the Administrative Board:  Bernard Fanget, (Vice President Pharmaceutical Development, Neovacs); Frank Oakes (CEO, Stellar Biotechnologies) and Miguel Sieler (CEO, Neovacs).

In addition, the management team will include Bernard Fanget as Chairman of the Board of Directors and President and Olivier Dhellin as CEO.  Both also will remain in their current positions at Neovacs.

Mr Fanget and Mr Dhellin’s experiences in the pharmaceutical industry are essential assets to oversee and ensure the efficient launch of the joint venture production company. Their first mission at Neostell will consist of identifying and reserve trough an option agreement a site for the manufacturing facility. However, major investment in the joint venture will not occur until after the results of the Neovacs ongoing Phase IIb trial with IFNa Kinoid in the treatment of lupus are known.

Neostell, with initial capital of 400,000 euros, will be based in the Paris area and set up to manufacture all kinoids developed by Neovacs, starting with IFNα-Kinoid, the company’s most advanced product candidate. Neostell also plans to manufacture and sell other KLH-based immunotherapy products for third-party customers worldwide. 

Bernard Fanget, Chairman and President of Neostell, said: « The Neostell corporation will first focus on the production scale-up of Neovacs’ IFN α -Kinoid immunotherapy in anticipation of a Korean market launch, as well as the planned Phase III trial for the treatment of lupus and the Phase IIa study in dermatomyositis . My objectives as president are to make Neostell operational, to effectively access the conjugated vaccines development market and to ultimately make Neostell a profitable business. »

“ This joint venture demonstrates Stellar’s commitment to ensuring that immunotherapy developers like Neovacs have both ample capacity of high-quality KLH as well as the infrastructure and expertise to manufacture their KLH-based immunotherapies as they advance to market,” said Frank Oakes, President , CEO and Chairman of Stellar Biotechnologies, Inc.   “With the Neostell corporation in place and its leadership appointed, we look forward to putting operational teams together to map out the next steps for this growth initiative .”  

About Bernard Fanget, Chairman of Neostell: Bernard leads pharmaceutical development activities at Neovacs. He brings more than 30 years of industrial experience in biologics pharmaceutical development. Bernard was Corporate Vice President, Global Industrialization at Sanofi Pasteur. He was previously Senior Vice President, Pharmaceutical Development of Flamel Technologies.

About Olivier Dhellin, CEO of Neostell: Olivier has 9 years of experience in immunotherapy development and cell-based vaccine manufacturing. He previously held positions at Anosys – a US/French cell therapy biotech company – and conducted research activities for 7 years at Gustave Roussy Institute (molecular biology and genomics) and Pasteur Institute, where he was a post-doctorate fellow in molecular pharmacology. Prior to that, he spent 4 years as a resident in several hospital departments (pediatrics, pharmacology and biochemistry). Olivier holds a degree in pharmacy (Paris XI University, France) and a PhD in virology (Pierre et Marie Curie University, France).

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (Nasdaq: SBOT ) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

About Neovacs

Neovacs is a leading biotechnology company that has a proprietary active immunotherapy technology platform (Kinoids) with applications in autoimmune and inflammatory diseases and cancer. The goal of the Kinoid approach is to enable patients to have access to safe, effective, long-lasting treatments for these often life-long diseases. Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for lupus and dermatomyositis. Neovacs also has several therapeutic vaccines in preclinical development for the treatment of autoimmune diseases, cancer and allergies. www.neovacs.fr

Contacts NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 cmasson@neovacs.com Investor Relations / Financial Communications Germany – MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries – The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 lroth@theruthgroup.com / jgreen@theruthgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 61

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 74

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 35

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 47

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 58

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 60

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 85

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 195

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading

Top 5 Most Recently Viewed Articles

Boots Group Wraps Up Consent Solicitation for Notes

Updated Category News Views 183

Consent Solicitation's Critical Role in Acquisition No time for dawdling—Boots Group's gathered up their consent cards for hefty senior secured notes, and we're talking close to a billion smackers here. It's a bold move to grease the wheels on looming acquisition maneuvers. We're looking at a €650 million and a £375 million stack of senior secured notes patiently...

Continue Reading
HUB Cyber Security Ltd. Welcomes Romke E. de Haan III

Updated Category News Views 120

HUB Cyber Security Ltd. Strengthens Leadership with New Appointment HUB Cyber Security Ltd. (NASDAQ: HUBC), a frontrunner in AI-driven cybersecurity solutions, has made a significant move by appointing Romke E. de Haan III as the Head of its Cybersecurity Strategy and Innovation Division. This pivotal role is expected to bolster the company's position within the North...

Continue Reading
Lisk EMpower Fund: Empowering Founders in Web3 Ventures

Updated Category News Views 177

Lisk EMpower Fund: A New Horizon for Web3 Startups The recently launched Lisk EMpower Fund is designed to support post-incubation Web3 startups in rapidly evolving markets, particularly in regions such as Africa, Latin America, and Southeast Asia. This initiative aims to bridge the gap in capital availability, providing opportunities for founders to achieve significant...

Continue Reading
BMO Capital Raises Datadog Price Target on Strong Revenue Outlook

Updated Category News Views 164

BMO Capital Shows Confidence in Datadog's Growth Recently, BMO Capital Markets demonstrated a strong belief in Datadog Inc (NASDAQ: DDOG), which operates a cloud-based monitoring and analytics platform. The firm raised its price target for the stock from $132.00 to $135.00 while maintaining an Outperform rating, reflecting their confidence in the company's ability to...

Continue Reading
Guru4Invest Introduces Revolutionary Security Upgrades

Updated Category News Views 555

Guru4Invest Strengthens Client Security with New Protocols In a significant move to bolster client safety and data integrity, Guru4Invest has rolled out advanced security protocols aimed at enhancing the protection of customer accounts and sensitive information. This decision reflects the company's steadfast commitment to security within the trading sector, showcasing...

Continue Reading